The New England Journal of Medicine has retracted the pivotal 2021 ADVOCATE trial that secured FDA approval for avacopan (Tavneos) , Amgen's treatment for severe ANCA-associated vasculitis. Two academic authors — David Jayne, MD, and Peter Merkel, MD, MPH — requested the retraction after discovering that nine patients' primary endpoint assessments were re-adjudicated after database lock and after the trial data had been unblinded — actions the journal...